Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRM Proteomics and PROOF Centre Collaborate with the Jain Foundation

Published: Tuesday, October 22, 2013
Last Updated: Tuesday, October 22, 2013
Bookmark and Share
The collaboration aims to identify blood-based biomarkers of LGMD2B/Miyoshi muscular dystrophy.

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and MRM Proteomics Inc. will use their biomarker expertise in collaboration with the Jain Foundation, Inc. to identify blood-based biomarkers of disease in individuals with a rare form of muscular dystrophy, called Limb‐girdle muscular dystrophy 2B (LGMD2B) or Miyoshi Myopathy (MM). Since no effective treatment exists for LGMD2B/ MM, this study is an essential step towards developing therapies for patients living with these debilitating muscle diseases.

LGMD2B/MM are both caused by mutations in the gene that encodes the protein dysferlin, which is thought to play a role in skeletal muscle repair collectively called “dysferlinopathies.”

The Jain Foundation chose to collaborate with MRM Proteomics and the PROOF Centre because of their excellent track record of discovering molecular biomarkers in blood and developing them into tests that aid in the diagnosis and treatment of other diseases.

“The Jain Foundation was impressed by the success PROOF Centre has had in moving biomarker programs from concept to the clinic, particularly with their recent clinical progress in finding a biomarker for rejection of a transplanted heart. We believe that pairing MRM Proteomics’ cutting edge expertise in mass spectrometry with PROOF’s unique clinical biomarker expertise, offers the greatest chance of identifying a biomarker to move our clinical program forward.” said Plavi MIttal, President and CEO, Jain Foundation

The study will compare blood samples from individuals with LGMD2B/MM with samples from healthy, age and gender-matched controls. Differences in proteins and nucleic acids in the blood that reflect differences in muscle function will be tested and validated as possible biomarkers. These biomarkers will then be used to help track disease progression and the efficacy of potential treatments in future clinical trials.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRM Proteomics and PROOF Centre of Excellence Partner to Bring New Diagnostic Tests to Clinic
Two British Columbian biotech organizations collaborate to optimize development of blood tests for patients with chronic organ disease.
Tuesday, October 02, 2012
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Peptides vs. Superbugs
Scientists successfully develop a shuttle system made of liquid-crystalline nanomaterials that protect peptites.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Immune Approach Targets Humans Instead of Bacteria
Scientists show for the first time how bacterial superantigen toxins work, and how short peptides can block them and save lives.
Could 2D Mass Spec Breakthrough Lead to Medical Revolution?
Pharmaceutical research could be quicker and more precise, thanks to an innovative breakthrough in 2D mass spec from the University of Warwick.
Less is More in Ribosome Assembly
Research uncovers genetic "program" that allows for ribosome formation with a limited supply of magnesium.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos